Nephronomics
Nephronomics applies genetic and clinical data to identify subtypes and mechanisms of cardio-kidney-metabolic disease to guide therapies. It uses exclusive access to the My Reason dataset (>35,000 patients), integrates clinical and genomic data, and employs ML models via the Nephronomics Atlas to uncover protective and disease-causing variants across the cardio-kidney-metabolic spectrum. The company operates as a precision medicine platform serving pharma and biotech, combining datasets and modeling tools to discover targets and inform treatments. Core technology includes genomics, clinical data integration, and machine learning models that power disease subtyping and mechanism discovery. As a joint venture with Fresenius Medical Care, Nephronomics aims to scale targeted therapies for CKM disease through large-scale data resources and analytics.
Nephronomics
Nephronomics applies genetic and clinical data to identify subtypes and mechanisms of cardio-kidney-metabolic disease to guide therapies. It uses exclusive access to the My Reason dataset (>35,000 patients), integrates clinical and genomic data, and employs ML models via the Nephronomics Atlas to uncover protective and disease-causing variants across the cardio-kidney-metabolic spectrum. The company operates as a precision medicine platform serving pharma and biotech, combining datasets and modeling tools to discover targets and inform treatments. Core technology includes genomics, clinical data integration, and machine learning models that power disease subtyping and mechanism discovery. As a joint venture with Fresenius Medical Care, Nephronomics aims to scale targeted therapies for CKM disease through large-scale data resources and analytics.